Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report

Yu Qiao; Jihong Yang; Lili Liu; Yixin Zeng; Jie Ma; Jing Jia; Li Zhang; Xiaoguang Li; Peihong Wu; Wenchao Wang; Dongge Liu; Huan Chen; Yunbo Zhao; Huan Xi; Yao Wang

doi:10.1186/s12885-018-3996-3

Successful treatment with pazopanib plus PD-1 inhibitor and RAK cells for advanced primary hepatic angiosarcoma: a case report

BMC Cancer. 2018 Feb 21;18(1):212. doi: 10.1186/s12885-018-3996-3.

Authors

Yu Qiao^{1

2}, Jihong Yang^{3

4}, Lili Liu^{1

5}, Yixin Zeng^{1

2}, Jie Ma⁶, Jing Jia¹, Li Zhang⁷, Xiaoguang Li⁸, Peihong Wu⁹, Wenchao Wang¹⁰, Dongge Liu¹¹, Huan Chen^{1

5}, Yunbo Zhao^{1

2}, Huan Xi¹, Yao Wang¹

Affiliations

¹ Department of Geriatric, Beijing Hospital, National Center of Gerontology, Beijing, 100730, People's Republic of China.
² Department of Oncology, Beijing Hospital, National Center of Gerontology, Beijing, 100730, People's Republic of China.
³ Department of Geriatric, Beijing Hospital, National Center of Gerontology, Beijing, 100730, People's Republic of China. yangjihong3078@bjhmoh.cn.
⁴ Department of Nephrology, Beijing Hospital, National Center of Gerontology, Beijing, 100730, People's Republic of China. yangjihong3078@bjhmoh.cn.
⁵ Department of Nephrology, Beijing Hospital, National Center of Gerontology, Beijing, 100730, People's Republic of China.
⁶ Biological Treatment Center, Beijing Hospital, National Center of Gerontology, Beijing, 100730, People's Republic of China.
⁷ Departmnet of Oncology, Tumor Hospital, Zhongshan University, Guangzhou, 510089, People's Republic of China.
⁸ Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Beijing, 100730, People's Republic of China.
⁹ The Center of Medical Image Guided Minimally Invasive Therapy, Tumor Hospital, Zhongshan University, Guangzhou, 510089, People's Republic of China.
¹⁰ Department of Imaging, Beijing Hospital, National Center of Gerontology, Beijing, 100730, People's Republic of China.
¹¹ Department of Pathology, Beijing Hospital, National Center of Gerontology, Beijing, 100730, People's Republic of China.

Abstract

Background: Primary hepatic angiosarcoma (PHA) is a rare and aggressive solid tumor, with high rates of local recurrence and distant metastasis, and poor prognosis. There are no established treatment guidelines for PHA.

Case presentation: A 78-year-old asymptomatic man with PHA that was successfully treated with pazopanib plus PD-1 inhibitor and RetroNectin-activated killer cells (RAK cells). After one month of treatment, there was a clear reduction in the size and number of the liver metastases; and after nearly 15 months, most of the lesions were stable, no new lesions had developed, and the side effect of treatment was minor.

Conclusion: Pazopanib, PD-1 inhibitor and RAK cells could serve as a potential option for the treatment of advanced PHA.

Keywords: PD-1 inhibitor; Pazopanib; Primary hepatic angiosarcoma; RAK cell.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Biopsy
Cell Line, Tumor
Combined Modality Therapy
Hemangiosarcoma / diagnosis*
Hemangiosarcoma / therapy*
Humans
Immunohistochemistry
Immunotherapy, Adoptive* / methods
Indazoles
Liver Neoplasms / diagnosis*
Liver Neoplasms / therapy*
Magnetic Resonance Imaging
Male
Neoplasm Metastasis
Neoplasm Staging
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Pyrimidines / administration & dosage
Sulfonamides / administration & dosage
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Indazoles
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Pyrimidines
Sulfonamides
pazopanib

Grants and funding

81373803/National Nature Science Foundation of China/International